Zoghbi Huda Y sold $640K of REGN

Zoghbi Huda Y sold 800 shares of REGENERON PHARMACEUTICALS, INC. (REGN) at $800.00 ($0.64M total) on 2026-08-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zoghbi Huda Y
Published Aug 12, 2026, 8:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REGN
Neutral
medium confidence
Mentioned
$REGN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REGNNeutralLow
01

Why it matters

The disclosed sale can be used for sentiment monitoring, but it does not introduce new company fundamentals such as earnings, guidance, trial results, approvals, or litigation outcomes.

02

Market read

Traders may note the insider sale for positioning and sentiment, but the filing alone is unlikely to drive a major repricing without accompanying fundamental news.

03

What to watch

10b5-1 plans reduce interpretability; the article does not provide context on total holdings, prior sales cadence, or whether other insiders also sold around the same period.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-12, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for Regeneron, reported by a director and executed as an open-market sale under a pre-arranged 10b5-1 plan.

Company-level read

Ticker impact

$REGNNeutralMedium confidence
Context

Regeneron director Zoghbi Huda Y filed a Form 4 open-market sale of 800 shares at $800 on 2026-08-10 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited and short-lived unless paired with other news.

Evidence & confidence

The filing is a routine 10b5-1 planned sale with a modest share count relative to a large-cap biotech, and the article provides no new operational, clinical, or regulatory catalyst.

Market effects

Minimal. Insider 10b5-1 sales are common and do not, by themselves, signal sector-wide changes.

None indicated.

None indicated.

Counterpoint

A cluster of insider sales (if corroborated by other filings) could indicate management is de-risking ahead of a known event, even when executed under 10b5-1.

Key entities

  • REGN

    Regeneron Pharmaceuticals, Inc., the subject issuer of the Form 4 insider transaction.

  • Zoghbi Huda Y

    Director who reported an open-market sale of 800 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REGNMed

These patients struggle with runaway bones. Finally there’s hope

The FDA approved two new treatments for fibrodysplasia ossificans progressiva (FOP), a rare genetic disorder. Regeneron's garetosmab (Pasatru) and Mirum's zilurgisertib (Atebrioz) reduce abnormal bone growth. FOP affects about 900 people worldwide, with limited mobility and shortened lifespans. Trials for pediatric use are ongoing.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$REGNHigh

Argus raises Regeneron stock price target on Dupixent strength

Argus raised its price target for Regeneron (REGN) to $1,050, citing strong growth in Dupixent sales, which rose 35% to $6.54B in Q3 2026. REGN's revenue grew 19% YoY, with analysts revising earnings estimates upward. The company's partnership with Sanofi now generates more revenue than its Eylea franchise. Other drugs like Libtayo and Praluent also showed significant sales growth. REGN's pipeline includes cenvacibart, with estimated peak sales of $2B-$4B if approved.

$SNYMed

Sanofi and Regeneron’s rare disease wins; Lilly’s dealmaking dance

Sanofi received FDA approval for Infilbray, the first treatment for neurological symptoms of type 3 Gaucher disease. Regeneron's Livsayis, for generalized myasthenia gravis, also gained approval but faces competition. Eli Lilly announced two cancer-focused deals: a $5.9B research agreement with Stipple Bio and a $1.5B acquisition of Calytrix Bio. Lilly's weight loss drugs face new FDA safety warnings.

$REGNMed

EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers

The European Commission approved an extended dosing schedule for cemiplimab (Libtayo), a cancer drug by Regeneron Pharmaceuticals, across all approved indications in skin, lung, and cervical cancers. The new schedule allows 700 mg every 6 weeks after 12 weeks of 350 mg every 3 weeks, with shorter infusion times. The decision follows a positive opinion from the European Medicines Agency. According to Regeneron, this aims to reduce patient burden and increase healthcare flexibility.

$REGNMed

FDA Approves First siRNA Therapy for AChR-Positive Myasthenia Gravis

Regeneron's Cemdisiran (Livsayis) received FDA approval for treating AChR-positive generalized myasthenia gravis (gMG). The siRNA therapy, dosed quarterly, showed significant improvements in clinical trials. Regeneron estimates 85,000 US patients may benefit. The therapy carries a boxed warning for meningococcal infections. Regeneron did not disclose launch date or pricing.